Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Win

7 Jul 2009 07:00

RNS Number : 2135V
ViaLogy PLC
07 July 2009
 



ViaLogy plc ("ViaLogy" or "the Company")

Boa Energy Resources contracts ViaLogy to develop multiple 

Oil & Gas lease properties

LondonJuly 7, 2009ViaLogy (LSE: viy) ViaLogy announces it has signed a services contract with Boa Energy Resources LLC of Houston, Texas ("Boa") Under the contract ViaLogy will provide analysis on a long term basis for Boa's oil and gas lease prospects using its proprietary QuantumRD reservoir characterization, sizing and subsurface interpretation technology. Boa's operating partner is Creed Energy LLC of Wichita Falls, Texas ("Creed")

Boa holds multiple leases with extensive drilling rights in Texas and Pennsylvania. ViaLogy's deliverables will include characterization of hydrocarbon reservoir boundaries, subsurface formations, lithology, and depth, as well as porosity estimates, and recommended drill locations.  ViaLogy will work in close partnership with Boa's and Creed's engineering and production staff.  QuantumRD is ViaLogy's proprietary active signal processing technology applied to seismic and geological data.  It provides a competitive advantage over conventional processing techniques in being able to discern subsurface features more accurately

Boa intends to drill multiple wells in this calendar year.  The first well will target a 4,000 foot plus depth formation on a 17,000 acre lease property in Clark County, Texas on which Boa has first refusal access Depending on QuantumRD analysis of the seismic, magnetic and satellite dataset, Boa and Creed plan to drill multiple wells on the site.  Contract terms provide ViaLogy with both a service fee and a success fee, paid as a working interest in the wells. 

Boa CEO Archie Ameigh commented, "We are impressed with the ViaLogy technology and believe it can make a real difference to our drilling success.  The broad applicability of QuantumRD to different types of formations and depths, and ViaLogy's one-stop ability to work with seismic and all forms of subsurface data are important to us as we develop our lease portfolio."

ViaLogy CEO Robert W. Dean said, "We are extremely pleased to have the opportunity to put QuantumRD to work for Boa and we are delighted to be co-operating with the experienced Creed Energy team We have agreed on an extended business partnership. Wintend to establish our technology as an industry standard."

Further information from:

ViaLogy

Robert W Dean, President & CEO

US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe

+44 (0) 1235-834734 (mobile: 07860 842756) 

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy

+44 (0) 20-7107-8000 

About ViaLogy: Network Centric Signal Processing

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology.  ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential.  ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter.  This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications.  For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTSSLFIMSUSEIW
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.